James Del Rosso, DO: JCAD June 2026 Issue Highlights

Fabrizio Galimberti, MD, PhD: The Importance of Targeted Therapy for GPP Treatment

Send us Fan Mail [https://www.buzzsprout.com/2179308/fan_mail/new] Fabrizio Galimberti, MD, PhD, reviews the molecular biology behind spesolimab for the treatment of generalized pustular psoriasis (GPP). He highlights the distinction between psoriasis and GPP, while discussing the role that the interleukin-36 pathway plays in inflammation. Dr. Galimberti emphasizes the importance of targeted treatment for flare reduction and improved outcomes in GPP management.

James Del Rosso, DO: JCAD June 2026 Issue Highlights

Send us Fan Mail [https://www.buzzsprout.com/2179308/fan_mail/new] James Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the June 2026 issue of JCAD.

Tina Bhutani, MD, MAS, FAAD: Use of Spesolimab for Generalized Pustular Psoriasis

Send us Fan Mail [https://www.buzzsprout.com/2179308/fan_mail/new] Tina Bhutani, MD, MAS, FAAD, discusses the use of spesolimab, an interleukin-36 receptor blocker, for the treatment of patients with generalized pustular psoriasis. Drawing on real-world patient cases, she highlights its role in rapidly controlling acute flares, improving patient quality of life, and reducing reliance on therapies originally developed for plaque psoriasis.

James Del Rosso, DO: JCAD May 2026 Issue Highlights

Send us Fan Mail [https://www.buzzsprout.com/2179308/fan_mail/new] James Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the May 2026 issue of JCAD.

Bruce Strober, MD, PhD, FAAD: Providing Care With Risankizumab in Psoriasis

Send us Fan Mail [https://www.buzzsprout.com/2179308/fan_mail/new] Bruce Strober, MD, PhD, FAAD, a clinical professor of dermatology at Yale University, discusses his extensive experience in treating patients with psoriasis. He describes his experience treating these patients with risankizumab (Skyrizi), highlighting its efficacy in treating chronic plaque psoriasis and its effectiveness for patients with comorbidities. The therapy has shown rapid improvement in high-impact areas of the body such as the scalp, palms, and soles. Dr. Strober emphasizes risankizumab's effectiveness in patients with psoriatic arthritis and those with low body surface area involvement, often making it a first-line systemic treatment for psoriasis.